IN2015DN03219A - - Google Patents
Info
- Publication number
- IN2015DN03219A IN2015DN03219A IN3219DEN2015A IN2015DN03219A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A IN 3219DEN2015 A IN3219DEN2015 A IN 3219DEN2015A IN 2015DN03219 A IN2015DN03219 A IN 2015DN03219A
- Authority
- IN
- India
- Prior art keywords
- pridopidine
- laquinimod
- treating
- neurodegenerative disorder
- provides
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 abstract 5
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 abstract 4
- 229960004577 laquinimod Drugs 0.000 abstract 4
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 4
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 abstract 4
- 229950003764 pridopidine Drugs 0.000 abstract 4
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Mechanical Engineering (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261706695P | 2012-09-27 | 2012-09-27 | |
| US201361879004P | 2013-09-17 | 2013-09-17 | |
| PCT/US2013/062482 WO2014052933A1 (fr) | 2012-09-27 | 2013-09-27 | Laquinimode et pridopidine pour traiter des troubles neurodégénératifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03219A true IN2015DN03219A (fr) | 2015-10-02 |
Family
ID=50339469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3219DEN2015 IN2015DN03219A (fr) | 2012-09-27 | 2013-09-27 |
Country Status (13)
| Country | Link |
|---|---|
| US (7) | US20140088140A1 (fr) |
| EP (1) | EP2900330A4 (fr) |
| CN (1) | CN104902958A (fr) |
| AU (1) | AU2013323131A1 (fr) |
| BR (1) | BR112015006623A2 (fr) |
| CA (1) | CA2884781A1 (fr) |
| EA (1) | EA201590655A8 (fr) |
| HK (2) | HK1211525A1 (fr) |
| IL (1) | IL237742A0 (fr) |
| IN (1) | IN2015DN03219A (fr) |
| MX (1) | MX2015003608A (fr) |
| WO (1) | WO2014052933A1 (fr) |
| ZA (1) | ZA201502600B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| WO2008127188A1 (fr) * | 2007-04-12 | 2008-10-23 | Allbay Ab | Dérivés n-oxyde et di-n-oxyde de stabilisateurs/modulateurs des récepteurs de la dopamine affichant des profils d'effets secondaires cardiovasculaires améliorés |
| EP2611759A1 (fr) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Analogues deutérés de pridopidine utiles en tant que stabilisants dopaminergiques |
| CA2847736A1 (fr) | 2011-09-07 | 2013-03-14 | IVAX International GmbH | Forme polymorphe de chlorhydrate de pridopidine |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| SG11201509729YA (en) | 2013-06-21 | 2015-12-30 | Teva Pharmaceuticals Int Gmbh | Use of high dose pridopidine for treating huntington's disease |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| EP3082814A4 (fr) * | 2013-12-20 | 2017-06-21 | Teva Pharmaceutical Industries Ltd. | Utilisation du laquinimod pour retarder la progression de la maladie de huntington |
| TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| CA2961187A1 (fr) * | 2014-09-16 | 2016-03-24 | Teva Pharmaceuticals Industries Ltd. | Traitement de maladies neurodegenerative avec une combinaison de laquinimod et de fingolimod |
| CA2970799A1 (fr) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | Sel de l-tartrate de pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| MX378579B (es) * | 2015-02-25 | 2025-03-11 | Prilenia Neurotherapeutics Ltd | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. |
| CA2993183A1 (fr) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Formulations a base de pridopidine et utilisation desdites formulations |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (fr) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combinaison de laquinimod et de pridopidine pour le traitement de la sclérose en plaques |
| EP4516356A3 (fr) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Utilisation de pridopidine pour le traitement du déclin fonctionnel |
| PL3570940T3 (pl) | 2017-01-20 | 2024-06-17 | Prilenia Neurotherapeutics Ltd. | Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x |
| US11253594B2 (en) | 2017-07-07 | 2022-02-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Drug combinations for protecting against neuronal cell death |
| EP4620471A3 (fr) * | 2017-08-14 | 2025-11-26 | Prilenia Neurotherapeutics Ltd. | Traitement de la sclérose latérale amyotrophique avec de la pridopidine |
| MX2021011269A (es) * | 2019-03-15 | 2021-10-01 | Prilenia Neurotherapeutics Ltd | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. |
| HRP20260072T1 (hr) * | 2019-06-12 | 2026-02-27 | Prilenia Neurotherapeutics Ltd. | Supstanca koja obuhvaća pridopidin i njegov analog za liječenje huntingtonove bolesti i njezinih simptoma |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2528040T3 (es) * | 2007-06-18 | 2015-02-03 | A.Carlsson Research Ab | Uso de estabilizadores de dopamina |
| CA2743717A1 (fr) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Derives d'azaquinolinone et leurs applications |
| AU2010282948C1 (en) * | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
| WO2011107583A1 (fr) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | 4-phényle-n-alkyle-pipéridines substituées destinées à prévenir le début ou à ralentir la progression de maladies neurodégénératives |
| MX2013006464A (es) * | 2010-12-07 | 2013-07-29 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple. |
-
2013
- 2013-09-27 IN IN3219DEN2015 patent/IN2015DN03219A/en unknown
- 2013-09-27 EA EA201590655A patent/EA201590655A8/ru unknown
- 2013-09-27 CA CA2884781A patent/CA2884781A1/fr active Pending
- 2013-09-27 AU AU2013323131A patent/AU2013323131A1/en not_active Abandoned
- 2013-09-27 HK HK15112317.4A patent/HK1211525A1/xx unknown
- 2013-09-27 US US14/040,586 patent/US20140088140A1/en not_active Abandoned
- 2013-09-27 BR BR112015006623A patent/BR112015006623A2/pt active Search and Examination
- 2013-09-27 CN CN201380050913.8A patent/CN104902958A/zh active Pending
- 2013-09-27 EP EP13840841.4A patent/EP2900330A4/fr not_active Withdrawn
- 2013-09-27 US US14/426,327 patent/US20150209346A1/en not_active Abandoned
- 2013-09-27 MX MX2015003608A patent/MX2015003608A/es unknown
- 2013-09-27 WO PCT/US2013/062482 patent/WO2014052933A1/fr not_active Ceased
- 2013-09-27 HK HK16102362.8A patent/HK1214553A1/zh unknown
-
2015
- 2015-03-15 IL IL237742A patent/IL237742A0/en unknown
- 2015-04-17 ZA ZA2015/02600A patent/ZA201502600B/en unknown
-
2017
- 2017-07-20 US US15/655,580 patent/US20170319569A1/en not_active Abandoned
- 2017-11-02 US US15/801,703 patent/US20180133209A1/en not_active Abandoned
-
2018
- 2018-05-08 US US15/974,112 patent/US20180250285A1/en not_active Abandoned
- 2018-08-30 US US16/117,604 patent/US20180369228A1/en not_active Abandoned
- 2018-12-18 US US16/223,993 patent/US20190117639A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190117639A1 (en) | 2019-04-25 |
| US20180133209A1 (en) | 2018-05-17 |
| HK1214553A1 (zh) | 2016-07-29 |
| EP2900330A4 (fr) | 2016-05-25 |
| EP2900330A1 (fr) | 2015-08-05 |
| IL237742A0 (en) | 2015-05-31 |
| US20180250285A1 (en) | 2018-09-06 |
| US20180369228A1 (en) | 2018-12-27 |
| EA201590655A1 (ru) | 2015-12-30 |
| CA2884781A1 (fr) | 2014-04-03 |
| BR112015006623A2 (pt) | 2017-07-04 |
| EA201590655A8 (ru) | 2016-07-29 |
| CN104902958A (zh) | 2015-09-09 |
| WO2014052933A1 (fr) | 2014-04-03 |
| MX2015003608A (es) | 2015-06-05 |
| HK1211525A1 (en) | 2016-05-27 |
| AU2013323131A1 (en) | 2015-05-07 |
| US20170319569A1 (en) | 2017-11-09 |
| US20140088140A1 (en) | 2014-03-27 |
| US20150209346A1 (en) | 2015-07-30 |
| ZA201502600B (en) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03219A (fr) | ||
| HK1211483A1 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX394909B (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos | |
| MY168791A (en) | Carbamate compounds and of making and using same | |
| MX365835B (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
| PH12012502399A1 (en) | Combination therapy methods for treating proliferative diseases | |
| SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| MX2021005317A (es) | Composiciones y métodos para absorción transmucosa. | |
| PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| BR112012022552A2 (pt) | uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
| TN2016000498A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| MX349767B (es) | Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular. | |
| MX358512B (es) | Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva. | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| IN2013MU01155A (fr) | ||
| IN2013MU01252A (fr) | ||
| IN2013MU01154A (fr) | ||
| IN2013MU01247A (fr) | ||
| IN2013MU01248A (fr) | ||
| IN2013MU01249A (fr) | ||
| IN2013MU01250A (fr) |